FilingReader Intelligence
Henlius gains FDA approval for thymic carcinoma trial
August 7, 2025 at 10:21 AM UTC•By FilingReader AI
Shanghai Henlius Biotech received FDA approval to begin a Phase 1 clinical trial of HLX43, an anti-PD-L1 antibody-drug conjugate, for thymic carcinoma in the United States.
HLX43 is already in Phase 1 and Phase 2 trials in China for various advanced solid tumors, including non-small cell lung cancer and esophageal squamous cell carcinoma.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:2696•Hong Kong Exchange
News Alerts
Get instant email alerts when Shanghai Henlius Biotech, Inc publishes news
Free account required • Unsubscribe anytime